33.23
price up icon2.75%   0.89
after-market 시간 외 거래: 33.23
loading
전일 마감가:
$32.34
열려 있는:
$32.34
하루 거래량:
869.76K
Relative Volume:
1.52
시가총액:
$1.86B
수익:
$651.97M
순이익/손실:
$59.71M
주가수익비율:
31.07
EPS:
1.0696
순현금흐름:
$172.03M
1주 성능:
-2.15%
1개월 성능:
+2.94%
6개월 성능:
-13.87%
1년 성능:
+9.85%
1일 변동 폭
Value
$32.20
$33.44
1주일 범위
Value
$32.20
$34.40
52주 변동 폭
Value
$27.05
$40.28

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name
명칭
Supernus Pharmaceuticals Inc
Name
전화
301-838-2500
Name
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
Name
직원
674
Name
트위터
@Supernus_Pharma
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
SUPN's Discussions on Twitter

SUPN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
SUPN
Supernus Pharmaceuticals Inc
33.23 1.90B 651.97M 59.71M 172.03M 1.0696
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
147.37 69.30B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.44 47.50B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.53 44.47B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.31 18.83B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
293.12 13.43B 2.99B 1.21B 1.13B 25.06

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-19 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2025-01-06 개시 Cantor Fitzgerald Overweight
2024-09-11 다운그레이드 Piper Sandler Overweight → Neutral
2023-01-03 재개 Jefferies Buy
2021-12-01 재개 Jefferies Buy
2021-04-13 업그레이드 Jefferies Hold → Buy
2020-06-16 업그레이드 Piper Sandler Neutral → Overweight
2020-06-15 재개 Jefferies Hold
2019-11-08 다운그레이드 Berenberg Buy → Hold
2019-11-07 다운그레이드 Stifel Buy → Hold
2019-11-06 다운그레이드 Jefferies Buy → Hold
2018-11-12 재확인 B. Riley FBR Buy
2018-01-18 재확인 B. Riley FBR, Inc. Buy
2017-12-28 재확인 B. Riley FBR, Inc. Buy
2017-12-04 업그레이드 Janney Neutral → Buy
2017-11-08 업그레이드 Stifel Hold → Buy
2017-10-19 개시 FBR & Co. Buy
2017-09-19 다운그레이드 Stifel Buy → Hold
2017-07-17 다운그레이드 Piper Jaffray Overweight → Neutral
2017-07-14 개시 Janney Neutral
2017-06-01 업그레이드 Piper Jaffray Neutral → Overweight
2016-07-18 다운그레이드 Northland Capital Outperform → Market Perform
2016-07-18 다운그레이드 Piper Jaffray Overweight → Neutral
2016-02-08 업그레이드 Jefferies Hold → Buy
2015-11-05 재확인 Northland Capital Outperform
2015-10-28 개시 Northland Capital Outperform
모두보기

Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스

pulisher
04:04 AM

What analysts say about Supernus Pharmaceuticals Inc. stockExceptional return forecasts - Autocar Professional

04:04 AM
pulisher
Jul 20, 2025

Supernus Pharmaceuticals Inc. Stock Analysis and ForecastSuperior stock selection - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Is Supernus Pharmaceuticals Inc. a good long term investmentExplosive trading opportunities - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox

Jul 19, 2025
pulisher
Jul 18, 2025

What drives Supernus Pharmaceuticals Inc. stock priceTremendous growth potential - Jammu Links News

Jul 18, 2025
pulisher
Jul 18, 2025

(SUPN) Investment Report - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 18, 2025

Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 15, 2025

Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Supernus Pharmaceuticals Inc. stock performs during market volatilityStrong Buy Recommendations - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Supernus Pharmaceuticals Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jul 15, 2025
pulisher
Jul 11, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Amalgamated Bank - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Allspring Global Investments Holdings LLC - Defense World

Jul 10, 2025
pulisher
Jul 08, 2025

When the Price of (SUPN) Talks, People Listen - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 02, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics in Transaction Valued Up to $795 Million - Global Legal Chronicle

Jul 02, 2025
pulisher
Jun 30, 2025

Busy Philipps, Jay Glazer highlight ADHD experiences in Supernus’ campaigns - Medical Marketing and Media

Jun 30, 2025
pulisher
Jun 27, 2025

Sage Therapeutics cuts over 300 jobs after securing buyer - The Business Journals

Jun 27, 2025
pulisher
Jun 23, 2025

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years - Yahoo Finance

Jun 23, 2025
pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Apomorphine Delivery Device Market Set to Witness Significant - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360

Jun 16, 2025
pulisher
Jun 16, 2025

Deals of the day-Mergers and acquisitions - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus makes depression drug play with $795m Sage buyout - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to buy Sage for up to $795 million - Axios

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025

Supernus Pharmaceuticals Inc (SUPN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$71.56
price up icon 1.97%
$14.68
price down icon 0.68%
$8.90
price up icon 0.23%
drug_manufacturers_specialty_generic RDY
$14.55
price up icon 0.48%
$131.83
price down icon 0.14%
$293.12
price up icon 0.38%
자본화:     |  볼륨(24시간):